Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups by Vivas Consuelo, David José Juan et al.
 Document downloaded from: 
 
This paper must be cited as:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final publication is available at 
 
 
Copyright 
http://dx.doi.org/10.1016/j.healthpol.2014.01.012
http://hdl.handle.net/10251/43560
Elsevier
Vivas Consuelo, DJJ.; Usó Talamantes, R.; Trillo Mata, JL.; Caballer Tarazona, M.;
Barrachina Martínez, I.; Buigues Pastor, L. (2014). Predictability of pharmaceutical
spending in primary health services using Clinical Risk Groups. Health Policy. 116(2-
3):188-195. doi:10.1016/j.healthpol.2014.01.012.
Accepted Manuscript
Title: Predictability of pharmaceutical spending in primary
health services using Clinical Risk Groups
Author: David Vivas-Consuelo Ruth Uso´-Talamantes Jose´
Luis Trillo-Mata Maria Caballer-Tarazona Isabel
Barrachina-Martı´nez Laia Buigues-Pastor
PII: S0168-8510(14)00025-6
DOI: http://dx.doi.org/doi:10.1016/j.healthpol.2014.01.012
Reference: HEAP 3169
To appear in: Health Policy
Received date: 9-5-2013
Revised date: 18-12-2013
Accepted date: 14-1-2014
Please cite this article as: Vivas-Consuelo D, Uso´-Talamantes R, Trillo-Mata JL,
Caballer-Tarazona M, Barrachina-Mart´inez I, Buigues-Pastor L, Predictability of
pharmaceutical spending in primary health services using Clinical Risk Groups, Health
Policy (2014), http://dx.doi.org/10.1016/j.healthpol.2014.01.012
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 16
Ac
ce
pte
d M
an
us
cri
pt
Predictability of pharmaceutical spending in primary 
health services using Clinical Risk Groups 
David Vivas-Consuelo*; Ruth Usó-Talamantes**, José Luis Trillo-Mata**, Maria 
Caballer-Tarazona***, Isabel Barrachina-Martínez*, and Laia Buigues-Pastor*
*Research Centre for Health Economics and Management, Universitat Politècnica de València, Cno de 
Vera s/n Valencia, Spain.
**Valencian Community Government, Health Department (Conselleria de Sanitat). General Direction of 
Pharmacy and Pharmaceutical Products, PharmacoEconomics office, Valencia, Spain.
*** Faculty of Economics. Universitat de València
Correspondence to:
Prof. David Vivas
Research Centre for Health Economics and Management
Universitat Politècnica de València, 
Cno de Vera s/n Valencia, Spain.
dvivas@upv.es
Tel +34963877062
Fax +34963877962
Acknowledgements
This study was financed by a grant from the Fondo de Investigaciones de la Seguridad 
Social Instituto de Salud Carlos III, the Spanish Ministry of Health (FIS PI12/0037). 
The authors would like to thank members (Juan Bru and Inma Saurí) of the 
Pharmacoeconomics Office of the Valencian Health Agency. The opinions expressed in 
this paper are those of the authors and do not necessary reflect those of the afore-named. 
Any errors are the authors’ responsibility. We would also like to thank John Wright for 
Page 2 of 16
Ac
ce
pte
d M
an
us
cri
pt
the English editing.
Page 3 of 16
Ac
ce
pte
d M
an
us
cri
pt
Predictability of pharmaceutical spending in primary 
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1. Introduction
Pharmaceutical expenditure is nowadays one of the most important and increasing 
factors in financial terms in healthcare in European countries [1]. Therefore, explaining 
the variations of expenditure on medicines is of paramount value. Due to the fact that 
patient complexity is a major determinant of expenditure, methodologies aimed at 
allocating an average pharmaceutical expenditure by specific patient characteristics are 
of great use in monitoring the range of prescription of medicines and therefore 
pharmaceutical expenditure. 
There are different grouping systems based on existing administrative and clinical data 
that can explain and predict pharmaceutical expenditure. Some of these are based on 
electronic prescription information, such as WHO-ATC and the Rx models [2-5]. Others 
are based on diagnoses: Clinical Risk groups (CRGs) [6, 7], Adjusted Clinical Groups 
(ACGs) [8] and Diagnostic Cost Groups, (DCG). Finally there are the mixed models
that combine both - Diagnostic Cost Groups, (DCG/Rx) [9] and Adjusted Clinical 
Groups (ACG/Rx) [10].The usefulness of these models is especially relevant for 
integrated health systems such as National Health Systems.
These tools described above also allow stratification of the population according to 
morbidity, which permits patients with the greatest risk to benefit from case 
management programmes. This improves the quality of care and life, as this system 
allows individuating the specific state of health of the population and makes it possible 
for patients to be introduced into disease management programmes.
This paper focuses on testing the suitability of CRGs for predicting expenditure in 
pharmacy budget allocation in an Autonomous Community in Eastern Spain. We also 
show the importance of using local weighting as opposed to standard weighting [7].
The Valencian health system and pharmaceutical management
This study was carried out in the Valencia Community (VC) in Spain, where 
pharmaceutical management is decentralised, being divided into 24 health districts. 
Each health district receives an annual per capita amount to attend to its assigned 
population. The flow of incoming and outgoing patients to and from other health 
districts generates an inter-centre turnover to establish the corresponding economic 
compensation [11]. The allocated budgets include a specific section for pharmaceutical 
expenditure that, at present, is adjusted only by socio-demographic variables, such as 
age, sex and pharmaceutical co-payment. The adjustment was made using a 
Standardized Amount Indicator built with the above-mentioned variables that allocated 
a cost per equivalent patient standardized [12]. The predictive level of this model is 
lower than 15%. This low percentage is basically due to the non-inclusion of morbidity 
variables, which best serve to explain the behaviour of pharmaceutical expenditure, but 
nevertheless are not reflected in the current budget allocation for health departments.
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Some research exists using different grouping systems for predicting or studying total 
health expenditures [3-6, 13], but we lack research using these methods to focus 
specifically on pharmacy expenditure [14, 15].
The adjustment by chronic conditions that CRG classification provides offers a great 
innovation for pharmaceutical management in allowing the rationalization of 
pharmaceutical expenditure. The VC has introduced tools over recent years that have
the objective of establishing clinical criteria that improve efficiency in pharmaceutical 
prescription. Given that the clustering criteria of CRG classification is based on 
unhealthy and chronic conditions, this system provides the doctor with information 
about the severity of his patients and an adjusted pharmaceutical expenditure forecast. 
This is only possible with a reliable and comprehensive Electronic Health Record 
(EHR), where all clinical encounters and coded diagnostics of patients in the different 
health care system settings are registered [16].
Previously, when a reliable EHR was not available, prescription data and WHO-ATC 
codes were used to establish the risk adjustment system [17]. However, although this 
system achieves a high explicative power for pharmaceutical expenditure, it is difficult 
to operate and has poor clinical use, as it is not connected with the EHR and a regular 
cross section calculation of weights is necessary. In the VC, the CRG system is in a 
period of implementation and testing.
The Clinical Risk Groups
We have chosen Clinical Risk Groups (CRGs) as it is a system that classifies individuals 
into mutually exclusive categories with clinical significance [18]. Using enrolment data, 
claims or other encounter level data, this system assigns each person with a chronic 
health condition to a severity level. CRG classification of the individual is by medical 
care services used over an extended period of time.
All groups can be classified into 9 statuses from healthy individuals to individuals with 
catastrophic condition. CRGs (1,079 groups) are consolidated into three tiers of 
aggregation referred to as Aggregated Clinical Risk Groups (ACRGs). The three 
successive tiers of aggregation are referred to as ACRG1 (416 groups), ACRG2 (151 
groups) and ACRG3 (38 groups), with ACRG3 being the highest level of aggregation, 
consisting of severity adjusted statuses. Each successive tier maintains status and 
severity levels while reducing the number of groups. Although the aggregation of CRGs 
reduces clinical precision, it maintains clinical meaningfulness. The ACRGs take into 
consideration the future medical care needs and clinical similarity of the individuals 
assigned to them.
The CRG system can be used to understand patterns of health service use and 
consumption and to develop applications for risk and price adjusting [7], although their 
use in pharmaceutical expenditure adjustment has not been tested [15]. The main 
clinical and managerial characteristic is their ability to identify patterns of 
pharmaceutical consumption in relation to the chronic conditions of a determined 
patient. For example, should a group of patients with an excessive pharmaceutical cost 
be identified, it can determine if this is related to the chronic condition they have and 
help establish corrective measures.
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The principal difficulty with the use of CRGs is the need for exhaustive and reliable 
information on diagnoses and use of health care services over a long period of time 
(minimum one year). Therefore, when this information is not available, the ATC model 
may be a suitable option.
To obtain the CRGs we used 3M™ Clinical Risk Grouping Software v.1.4. CRGs 
capture the resource utilization of all inpatient and ambulatory encounters, identifying 
individuals with multiple chronic co-morbid conditions and explicitly specifying the 
severity of illness for each individual
The main aim of this paper is to test the suitability of the model based on the CRG 
system and obtain specific adjusted weights for determined health states through a 
predictive model of pharmaceutical expenditures in primary health care.
In this study, we developed a predictive model based on CRG grouping into 9 health 
states and the weights for each state were calculated using real data. We used an 
appropriate comparison system, described in a recent work [17], the ATC-model, a 
retrospective model that classifies patients according to the number of chronic 
conditions in 9 groups, from healthy to those with 8 chronic diseases or more and also 
includes gender.
2. Data and Methods
2.1. Data
We used information from a population of 261,054 between January - December 2008, 
taken from one health district of the VC, which contains 24 health districts connected by 
a single integrated EHR . Data for each patient included in the study was obtained from 
the Ambulatory Information System, integrated in the EHR of the Valencia Health 
Agency of the Generalitat Valenciana (Autonomous Health Department). The 
Population Information System from the Valencia Health Agency provided demographic 
information. All case IDs used for data linkage were encrypted according to the data 
protection law in Spain. 
The general practitioner uses an EHR for collected patient health information generated 
by each meeting in any care delivery setting. It includes patient demographics, progress 
notes, problems, medications, vital signs, past medical history, immunizations, 
laboratory data and radiology reports, as well as a specific module for electronic 
prescriptions that is coded using WHO-ATC codes [19] and the number of defined daily 
doses (DDD).
The variables considered were: annual pharmaceutical expenditure by patient, gender (1 
woman and 0 man), age, pharmaceutical co-payment status (1 for without co-payment 
and 0 for a co-payment of 40%), 18 groups of ATC-code as proxy for 18 chronic 
conditions; 9 Health Status of ACRG3 assignment. At the time of the study, Spain had
only co-payment for medicines, with two categories of co-payment - pharmacy gratuity 
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for pensioners and population without resources, and co-payment of 40% for others1.
The grouping system based on prescription and ATC-model considers 9 groups. The 
first group are persons without chronic conditions, with successive groups up to the 9th
depending on the number of chronic conditions from 1 to 8 or more. 
Table 1 shows the ATC-code related with each chronic condition and the number of 
patients who have received at least 5 prescriptions per year. We use a classification of 
medicines validated by Lamers LM and van Vliet RC [4] and modified by Vivas D et al
[17].
2.2. Mathematical models
Two models were developed to explain pharmaceutical expenditure in primary health 
care. The dependent variable was always the neperian log of annual pharmaceutical 
expenditure by patient. The logarithm of the pharmaceutical expenditure is estimated as 
a better approach to its normal distribution of the variable, due the asymmetric 
probabilistic function of this variable. 
Age and co-payment status were excluded due to the high correlation with the chronic 
condition classification and health status. However demographic variables such as age 
or gender have a low weight in the models when morbidity variables are introduced.[20, 
21]. In both models the healthy group (patients with no chronic disease) was the control 
variable necessary in the regression model.
As independent variables for the first model (ATC-model) we take the following 
dummy variables: X1 sex (0 man,1 woman); X2 to X9 variables for groups from 1 to 8 
or more chronic conditions: 
Y = α + β1 X1 + β2 X2 + β3 X3 +….+ β9 X9+ ε      (1)
Where:
α: is the constant of the model which corresponds to the weight for a male patient 
without chronic conditions.
β1: is the weight corresponding to sex
β2, ..,β9:are the weights corresponding to the number of chronic conditions of the 
patients.
ε: is the standard error of the model
In the second model (CRG-model) we also include sex (X1) and from X2 to X9, 8 
                                               
1Since 24 of April 2012 the pharmaceutical co-payment was changed. Among others 
measures, pensioners pay 10% and general workers 50%. Real Decreto-ley 16/2012.
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dummy variables for health statuses 2 to 9 of ACRG3 assignment:
Y = α + β1 X1 + β2 X2 + β3 X3 +…+ β9 X9 + ε       (2)
Where:
α: is the constant of the model which corresponds to the weight for a male patient who 
belongs to healthy group.
β1: is the weight corresponding to sex
β2, ..,β9: are the weights corresponding to the status 2 to 9 of ACRG3 assignment.
ε : is the standard error of the model
The models were estimated by means of ordinary least squares (OLS). The goodness of 
fit was determined through the corrected R
2
 value and the F Snedecor, mean squared 
error, and for each of β coefficients t-Student values were obtained to determine the 
level of significance. The assumptions of normality, homoscedasticity and linearity were 
considered.
The statistics to test the multicollinearity was the Condition Number Test. The 
Condition Number is computed by finding the square root of the maximum eigenvalue 
divided by the minimum eigenvalue. If the Condition Number is above 30, the 
regression is said to have significant multicollinearity. Also a formal detection-tolerance 
or the variance inflation factor (VIF) for multicollinearity was obtained.
The linear regression models allow us to explain the neperian log of pharmaceutical 
expenditure (dependent variable Y) in function of each considered independent variable 
(Xi). The mathematical expression is:
Pharmaceutical expenditure = e(∝+β1.x1+……..+βn.Xn)        (3)
3. Results
Table 2 shows the number of patients classified using the ATC-model in nine groups 
from healthy to 8 or more chronic conditions. The percentage of patients logically 
decreases in relation to the number of chronic conditions from 38.6% in the healthy 
group to 2.3% in the group with 8 or more conditions. The average cost increases from 
16.9 to 1,979 Euros. It can be seen that the standard deviation shows a high variability 
of cost.
The grouping results for the CRG system are presented in Table·3. Here, 52.1% were 
considered as healthy, which is lower than figures reported for this status by other 
scholars using a less reliable diagnostic codification [22]. The average cost also 
increased from 42 Euros for a healthy person to 2,210 for status 7, though was less than 
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expected for statuses 8 and 9. These groups include malignancies and catastrophic 
diseases for which patients are treated in hospitals, where consumed medicine is not 
dispensed in PHCs
The results for CRG aggregation level 3 (ACRG3) are presented (table 3) including the 
severity level established in this agregation for each health status. Two values were 
calculated for each group, one representing the average cost in pharmacy and the other 
the number of patients as a percentage of the total. This is the traditional manner of 
presentation of this assignment level. Thus, Table 3 gives us a picture of morbidity 
distribution of the population studied.
The pharmaceutical cost observed in certain severity levels of some health statuses do 
not correlate with weights given in the original theoretical model [7]. No significant 
difference in number of patient distribution was obtained, except for statuses 4 and 6, 
where a difference was also observed in severity levels.
The patients of health statuses 5 (single dominant or moderate chronic disease) and 6 
(chronic disease in 2 or more organs) represent 26% of the population but consume 57.5 
million Euros annually, 73.71% of the total consumption. This is due to these statuses 
containing the highest number of dominant chronic disease sufferers, such as 
hypertension, diabetes or hyperlipidemia. It is not possible to infer this type of 
discrimination with the ATC model.
From a statistical point of view, in the ATC model the total cost of the groups tends to 
be evenly distributed over the different groups, while the CRG model offers us a 
classification corresponding more to the clinical reality (tables 2 and 3).
With the regression model developed we obtain weights specific for pharmaceutical 
expenditure, which is the important contribution this paper offers to groups working in 
this area. The levels of explanation by R
2
 of both models are similar, with 52.5% for 
ATC-model (Table 4) and 47.5% for CRG (Table 5), despite the higher complexity of 
CRG. Small but significant differences by gender are appreciated, with men receiving
fewer prescriptions than women on average. 
From the coefficients obtained in the CRG model, undoing the neperian log 
transformation we obtain a standard cost for health status by sex that allows us to 
establish the specific standard costs for the CRG for pharmaceutical expenditure in 
primary health care, adapted for the region of application.
4. Discussion
This study is intended to examine the usefulness of CRGs as a method of risk 
adjustment in pharmaceutical management in primary health care. The validation of its 
predictive power was made comparing it to a non-hierarchical model using the ATC-
model. The predictive power obtained from these two models is 0.525 for the ATC-
model and 0.475 for the CRG[15]. Both of these models reach similar levels to those 
found with ACG [8, 23] and DCG/HCC [24].
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Initial studies found that demographics alone have very low predictive power [10]. The 
introduction of diagnosis cost group/hierarchical conditions categories (DCG/HCC) 
greatly improves the predictive power compared to models that use sex and age alone as 
independent variables [24].
The ACG case-mix system has been used in some PHCs in Spain and validated in a 
study using data from an entire Canadian province [8]. These authors found that the 
ACG case-mix system predicted drug expenditure better than the Charlson index of 
comorbidity. The squared correlation reached from ACGs was 0.24 , with the Charlson 
giving 0.14. On the other hand, a study of Aragon, Spain, (n=84,152) using DxRx-ACG 
with Spanish case-mix calibration reached 42% of explanation. [23]
The ATC-model used as comparison with CRGs is obtained grouping the number of 
chronic conditions from 1 to 8 or more from data provided by an electronic prescription 
system. The main advantage is the reliability of data but the clinical significance is poor. 
This is because it indicates only the number of chronic diseases of the patient and not 
the specific illness itself, making it impossible to use in programmes for disease 
management.
The CRG model is more useful from the clinical point of view. In the context of 
European and the Spanish National Health Systems, the weights obtained in the 
regression models could be used to establish a pharmacy capitation system in order to 
assign pharmaceutical budgets to health districts and PHCs. In the V C, the Health 
Department is developing an interactive computer tool to monitor the pharmacy 
expenditure from health district to doctor level. Using CRGs the doctor may then 
identify deviations from the predicted model. Chronic disease management programmes 
based on CRG patient stratification are also in the process of implementation. We see 
this as the main contribution in terms of health policy making.
The limitation of the CRG model is that obtaining the information for grouping is 
complicated. This system is designed for adjusting total health spending, and it would 
be appropriate to include the hospital pharmaceutical cost in the model. Other, wider 
studies need to be made of various years, comparing cohorts of patients in order to 
improve the information and to compare the predictive power.  
5. Conclusion
The potential of the CRG model developed using locally specific weights compared to 
models using to ATC codes lies in its high capacity to stratify the population according 
to specific chronic conditions of the patients, in such a way that we are able to know the 
degree of severity of a patient or group of patients, predict their pharmaceutical cost and
establish specific programmes for their treatment. As this paper shows that the 
explicative power of the proposed model is very similar to that of the model used for 
comparison, this means in practice, and if local weights are used, a highly relevant 
advance in pharmaceutical management in terms of improving prescription efficiency 
and management of chronic patients.
Therefore, even though the levels of explanation obtained in both models are quite 
similar, the CRG model shows some strength from an operational point of view. The 
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explicative capacity of CRG for pharmaceutical expenditure is useful in comparison 
with the ATC-model, as the ATC-model must be calculated retrospectively from the 
WHO- ATC Codes prescribed at a specific time, while the CRG model is available in 
real time, taking the information from the electronic clinical report. In addition CRG 
model has a greater potential to manage patients with chronic conditions and monitor 
pharmaceutical expenditure and medicine use. 
Although the validity of the predictive power may require further research to refine the 
model, much of its potential relies on the development of a sufficiently powerful IT tool 
capable of managing the large amount of information it offers.
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Table 1. Number and percentage of patients by 18 chronic conditions
Chronic conditions ATC-code and description
Number of 
patients
Percentage
Cardiac disease / 
ASCVD/CHF*)
C01. CARDIAC THERAPY; C03C. HIGH-CEILING DIURETICS
C03EB01. FUROSEMIDE AND POTASSIUM-SPARING AGENTS
27949 10.7
Crohn’s and ulcerative colitis
A07EC, (EXCLUDING A07EC01). AMINOSALICYLIC ACID AND SIMILAR 
AGENTS.
1134 0.4
Coronary and peripheral 
vascular disease
B01A. ANTITHROMBOTIC AGENTS; C04AD03. PENTOXIFYLINE 44757 17.1
Cystic fibrosis A09AA02. MULTIENZYMES (LIPASE, PROTEASE, ETC.) 67 0.02
Depression 
N06AA. NON-SELECTIVE MONOAMINE REUPTAKE INHIBITORS 
N06AB. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
N06AF. MONOAMINE OXIDASE INHIBITORS, NON-SELECTIVE
N06AG. MONOAMINE OXIDASE A INHIBITORS
N06AX. OTHER ANTIDEPRESSANTS
36576 14.0
Diabetes 
A10A. INSULINS AND ANALOGUES;
A10B. BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
22326 8.6
Epilepsy N03A, (EXCLUDING N03AE01). ANTIEPILEPTICS 14357 5.5
Glaucoma S01E. ANTIGLAUCOMA PREPARATIONS AND MIOTICS 11865 4.5
Gout M04A. ANTIGOUT PREPARATIONS 7001 2.7
Hyperlipidemia C10A. LIPID MODIFYING AGENTS, PLAIN 44885 17.2
Hypertension 
C02. ANTIHYPERTENSIVES;  C03A. LOW-CEILING DIURETICS, THIAZIDES;
C07. BETA BLOCKING AGENTS; C08. CALCIUM CHANNEL BLOCKERS; 
C09A. ACE INHIBITORS, PLAIN; C09B.  ACE INHIBITORS, COMBINATIONS;
C03EA01. HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS
47438 18.2
Parkinson’s disease N04B. DOPAMINERGIC AGENTS 1820 0.7
Peptic acid disease
A02A. ANTACIDS; A02B. DRUGS FOR PEPTIC ULCER AND GASTRO-
OESOPHAGEAL REFLUX DISEASE (GORD)
100836 38.6
Psychotic illness (including 
bipolar disorders)
N05A. ANTIPSYCHOTICS
22610 8.7
Respiratory illness, asthma R03. DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 46144 17.7
Rheumatologic conditions
H02. CORTICOSTEROIDS FOR SYSTEMIC USE;
M01CB. GOLD PREPARATIONS; M01CC01. PENICILLAMINE;
P01BA02. HYDROXYCHLOROQUINE;  L01BA01. METHOTREXATE;
A07EC01.  SULFASALAZINE
26349 10.1
Thyroid disorders H03A. THYROID PREPARATIONS; H03B. ANTITHYROID PREPARATIONS 9814 3.8
Transplantations L04AA06. MYCOPHENOLIC ACID; L04AX01. AZATHIOPRINE 1094 0.4
Tuberculosis J04A. DRUGS FOR TREATMENT OF TUBERCULOSIS 536 0.2
*ASCVD: arteriosclerotic cardiovascular disease, CHF: congestive heart failure.
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Table 2. Patients and pharmaceutical cost by groups of patients from chronic 
conditions classification.
Groups Number of 
patients
Percentage of 
patients
Total 
pharmaceutical
Cost €
Average cost per 
patient 
Cost €
Standard 
deviation
Healthy 100,717 38.6 1,700,484.4 16.9 104.0
1 chronic condition 54,128 20.7 4,531,361.3 83.7 411.8
2 chronic conditions 33,864 13.0 7,062,282.1 208.5 555.8
3 chronic conditions 21,906 8.4 9,261,226.9 422.8 891.8
4 chronic conditions 16,464 6.3 11,052,095.7 671.3 991.5
5 chronic conditions 12,730 4.9 12,019,569.5 944.2 1,245.1
6 chronic conditions 9,078 3.5 11,203,307.9 1,234.1 1,380.6
7 chronic conditions 6,215 2.4 9,420,092.4 1,515.7 1,601.4
8 or more chronic 
conditions
5,952 2.3 11,780,342.6 1,979.2 1,837.0
Total 261,054 100.0 78,030,762.8 298.9 830.5
Page 14 of 16
Ac
ce
pte
d M
an
us
cri
pt
Table 3. Number of persons, percentage and average cost by category and CRG 
severity level
Severity level
CRG Status 0 1 2 3 4 5 6 Total
135,988 135,988
a
52% 52.1%
b
1. Healthy
42.0 42.0 €
c
5,713,475€
d
18,377 18,377
7% 7%
2. History of significant acute 
disease
60.3 € 60.3 €
1,108,443€
16,600 6,559 23,159
6.36% 2.51% 9%
3. Single minor chronic disease
135.6 € 128.1 € 133.5 €
3,090,863€
4,682 1,352 3,921 1,885 11,840
1.79% 0.52% 1.50% 0.72% 4.54%
4. Minor chronic disease in 
multiple Organ Systems
222.5 € 354.1 € 283.9 € 387.1 € 284.1 €
3,363,449€
18,604 9,897 1,632 184 294 43 30,654
7.13% 3.79% 0.63% 0.07% 0.11% 0.02% 11.75%
5. Single dominant or moderate 
chronic disease
500.9 € 443.1 € 844.3 € 905.3 € 1,202.5 € 2,335.1 € 512.2 €
15,701,856€
19,733 7,813 5,437 3,078 12,18 181 37,460
7.56% 2.99% 2.08% 1.18% 0.47% 0.07% 14.35%
6. Chronic disease in 2 or more 
Organ Systems
863.8 € 1,156.0 € 1,419.1 € 1,674.2 € 2,091.7 € 1,777.2 € 1,116.2 €
41,814,669€
552 374 700 226 167 63 2,082
0.21% 0.14% 0.27% 0.09% 0.06% 0.02% 0.80%
7. Dominant Chronic Disease in 
3 or more Organ Systems
2,021.1 € 2,055.9 € 2,286.3 € 2,377.7 € 2,543.4 € 2,459.8 € 2,210.4 €
4,602,060€
90 264 378 237 63 1,032
0.03% 0.10% 0.14% 0.09% 0.02% 0.40%
8. Dominant and  Metastatic 
Malignancies
1,049.0 € 1,273.4 € 2,064.2 € 2,194.9 € 1,530.9 € 1,770.8 €
1,827,477€
59 166 75 86 53 23 462
0.02% 0.06% 0.03% 0.03% 0.02% 0.01% 0.18%
9. Catastrophic conditions
1,826.2 € 1,284.4 € 2,001.0 € 1,804.2 € 2,341.5 € 2,529.7 € 1,749.9 €
808,472€
Total 15,4365 60,320 26,425 12,143 5,696 1,795 310 261,054
% 59.13% 23.11% 10.12% 4.65% 2.18% 0.69% 0.12% 100%
a: number of patients; b: percentage of patients; c: average cost per patient of this group; 
d: total pharmaceutical cost of this group
Table 4. Regression model 1 with ATC chronic diseases number of medicines as 
independent variables
Unstandardized 
coefficients 
Standardize
d 
coefficients t Sig.
Average 
cost 
women €
Average 
cost men €
Multicollinearity 
statistics
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Variables
B
Standar
d error
Beta women € Tolerance VIF
Constant
1.085 0.007 166.335 0.000
Sex
0.265 0.007 0.051 37.328 0.000 0.991 1.009
Without chronic 
condition
3.9 3.0
1 chronic condition
1.377 0.010 0.213 143.113 0.000
15.3 11.7
0.820 1.220
2 chronic 
conditions 2.478 0.011 0.318 218.400 0.000
46.0 35.3
0.858 1.165
3 chronic 
conditions 3.470 0.013 0.367 257.564 0.000
124.0 95.1
0.894 1.119
4 chronic 
conditions 4.275 0.015 0.397 281.341 0.000
277.3 212.7
0.914 1.094
5 chronic 
conditions 4.836 0.017 0.398 284.558 0.000
485.9 372.8
0.931 1.074
6 chronic 
conditions 5.248 0.020 0.367 265.148 0.000
733.6 562.8
0.948 1.054
7 chronic 
conditions 5.536 0.024 0.322 234.558 0.000
978.5 750.7
0.964 1.038
8  or more chronic 
conditions 5.873 0.024 0.335 243.844 0.000
1,370.6 1,051.5
0.965 1.036
Statistics
Mean Square error 3.2 F 32093.8
R2 52.5 CN 3.537
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Table 5. Regression model 2 with CRG health Statuses as independent  variables
Unstandardize
d coefficients
Standar
dized 
coefficie
nts
Multicollinearity 
statistics
B
Stand
ard 
error
Beta
t
Sig. Average 
cost 
women 
€
Average 
cost 
men €
Tolerance VIF
Constant
1.511 0.006 246.275 0.000
Sex
0.202 0.008 0.039 26.860 0.000 0.979 1.022
7. Healthy 5.5 4.5
2 History of significant acute 
disease 1.064 0.015 0.104 71.287 0.000
16.1 13.1
0.947 1.056
3 Single minor chronic disease
1.607 0.014 0.174 118.803 0.000
27.7 22.6
0.933 1.072
4 Minor chronic disease in 
multiple Organ Systems 2.754 0.018 0.219 150.738 0.000
87.1 71.2
0.955 1.047
5 Single dominant or moderate 
chronic disease 3.250 0.012 0.399 270.465 0.000
143.0 116.9
0.923 1.084
6 Chronic disease in 2 or more 
Organ Systems 4.634 0.011 0.620 415.681 0.000
570.8 466.4
0.904 1.107
7 Dominant Chronic Disease in 3 
or more Organ Systems 5.607 0.042 0.190 133.767 0.000
1,510.2 1.234.0
0.993 1.007
8 Dominant and  Metastatic 
Malignancies 4.346 0.059 0.104 73.273 0.000
427.9 349.7
0.996 1.004
9 Catastrophic conditions
4.191 0.088 0.067 47.378 0.000
366.5 299.5
0.998 1.002
Statistics
Mean 
Square 
error
3.6 F 26,215.9
R2 47.5 CN 3.06
